A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
NCT ID: NCT06436183
Last Updated: 2025-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
62 participants
INTERVENTIONAL
2024-05-01
2025-08-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis
NCT05614817
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06130566
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
NCT06718101
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
NCT04313400
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
NCT01756898
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Part 1 (Blinded Period):
Eligible patients will be randomized in a 1:1:1 ratio to receive either camoteskimab dose 1, camoteskimab dose 2 or placebo.
Part 2 (Extension Period):
In part 2, all participants will receive camoteskimab.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose 1
Camoteskimab
Camoteskimab
Drug Product
Dose 2
Camoteskimab
Camoteskimab
Drug Product
Placebo
Inactive substance
Placebo
Dummy version of the study drug
Placebo
Inactive substance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Camoteskimab
Drug Product
Placebo
Inactive substance
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Chronic AD for at least 1 year.
3. Participants with moderate to severe AD defined by:
1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Baseline.
2. AD involvement of ≥ 10% body surface area (BSA) at Baseline.
3. EASI score of ≥ 12 at Baseline.
4. Pruritus numerical rating scale (NRS) ≥ 4 at Baseline.
4. Participants who are candidates for systemic therapy, defined as inadequate response to treatment with topical medications, or for whom topical treatments are otherwise medically inadvisable.
5. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Female participants:
* Sexually active females of childbearing potential must agree to use two forms of accepted methods of highly effective forms of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes:
* IUD plus one barrier method.
* Stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method.
* 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or
* A vasectomized partner\*.
Male participants:
* Sexually active male participants and males and who are partners of females of childbearing potential agree to use two forms of contraception as above and to not donate sperm or try to conceive during the treatment period and for at least 3 months after the last dose of study drug.
6. Participant provides signed informed consent.
Exclusion Criteria
biologics or JAKi) and who used any of these medications as follows:
1. Dupilumab, tralokinumab, lebrikizumab within 8 weeks prior to Baseline.
2. Systemic JAKi within 4 weeks prior to Baseline.
3. TCS, TCI, topical phosphodiesterase-4 (PDE4) inhibitors, and topical JAKi within 7 days prior to enrollment (at Baseline) or more than five half-lives whichever is longer.
2. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments.
3. Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma).
4. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12- lead ECG as considered by the perfusion index that may interfere with the interpretation of QTc interval changes.
5. Participant has AD involving ocular symptoms, or blepharitis, conjunctivitis, or keratitis diagnosed within the last 60 days prior to the screening visit, requiring chronic ocular corticosteroid treatment.
6. Participant has severe or uncontrolled seasonal or allergic rhinitis, asthma or any other non-AD disease as judged by the Investigator. Participants with seasonal or allergic rhinitis, asthma or any other non-AD disease requiring use of intranasal or inhaled corticosteroid that is stable and well-controlled are not excluded.
7. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test; Active hepatitis B virus (HBV): confirmed hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+); Active hepatitis C virus (HCV): Confirmed hepatitis C antibody positive (+); evidence of active or latent TB
8. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of
* Completely resected basal call or squamous cell carcinoma of the skin.
* Carcinoma in situ of the cervix.
9. Has had previous exposure to anti-IL-18 therapy.
10. Treatment with any investigational agent, or any investigational device or procedure, within 28 days (or 5 half- lives, whichever is greater) of screening.
11. Has any of the following laboratory findings
1. Glomerular filtration rate (GFR) \< 30 mL/min/1.73 m2.
2. Hemoglobin ≤8 g/dL.
3. Neutrophils ≤1,500/μL.
4. Platelets ≤75,000/μL.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Apollo Therapeutics Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Dermatology Specialists, PC/US Dermatology Partners
Phoenix, Arizona, United States
California Dermatology & Clinical Research Institute
Encinitas, California, United States
First OC Dermatology Research, Inc.
Fountain Valley, California, United States
Center for Dermatology Clinical Research, Inc.
Fremont, California, United States
California Allergy and Asthma Medical Group
Los Angeles, California, United States
University of California Los Angeles Dermatology
Los Angeles, California, United States
Amicis Research Center (Northridge)
Northridge, California, United States
Cura Clinical Research
Oxnard, California, United States
VASDHS - Veterans Affairs San Diego Medical Center
San Diego, California, United States
Clinical Sciences Institute
Santa Monica, California, United States
Renaissance Research and Medical Group
Cape Coral, Florida, United States
D&H National Research Centers, Inc.
Miami, Florida, United States
Avita Clinical Research - Dermatology
Tampa, Florida, United States
Sneeze, Wheeze & Itch Associates, LLC
Normal, Illinois, United States
Dawes Fretzin Clinical Research
Indianapolis, Indiana, United States
Skin Sciences, PLLC
Louisville, Kentucky, United States
Owensboro Dermatology Associates
Owensboro, Kentucky, United States
Revival Research Institute
Troy, Michigan, United States
Somerset Skin Centre
Troy, Michigan, United States
Michigan Dermatology Institute
Waterford, Michigan, United States
Advanced Dermatology and Skin Cancer Center - Saint Joseph
Saint Joseph, Missouri, United States
Skin Specialists PC
Omaha, Nebraska, United States
M3 Wake Research, Inc.
Raleigh, North Carolina, United States
ObjectiveHealth-The Skin Surgery Center for Clinical Research
Winston-Salem, North Carolina, United States
Central Sooner Research
Oklahoma City, Oklahoma, United States
Unity Clinical Research - Dermatology
Oklahoma City, Oklahoma, United States
Paddington Testing Co. Inc
Philadelphia, Pennsylvania, United States
Rodgers Dermatology
Frisco, Texas, United States
Center for Clinical Studies
Houston, Texas, United States
Clinical Trial Network
Houston, Texas, United States
Youthful Image
Edmonton, Alberta, Canada
Rejuvenation Dermatology Clinic Edmonton South
Edmonton, Alberta, Canada
Kingsway Clinical Research
Etobicoke, Ontario, Canada
Clinique Medicale Saint-Louis
Québec, Quebec, Canada
Clinique Dermatologique de Sherbrooke
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AP43CP03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.